On just the second day of the newborn baby JK Muldoon's life, doctors noticed something was not right. While all babies sleep a lot, the doctors noticed that he was unusually sleepy. When a doctor raised his arm, it trembled and dropped limply. This is when the doctors noticed something and ran blood test. It revealed that the baby had high levels of ammonia in his body. The baby was suffering from carbamoyl-phosphate synthetase 1 (CPS1) deficiency. This is an ultra-rare genetic disorder that affects the liver's ability to breakdown ammonia. Half of babies with CPS 1 deficiency don’t survive infancy. Those who do often face severe neurological challenges. For KJ’s parents, Kyle and Nicole, early conversations included talk of liver transplants and even comfort care.CRISPR - genetic editing that saved the babyBehind all this, a revolution in medicine had already been underway. For years, scientists, clinicians, and regulators had been preparing for a moment like this where gene-editing tools like CRISPR that earned the Nobel Prize in 2020 could be put to use to create a personalized treatment for rare genetic diseases. At Children’s Hospital of Philadelphia and Penn Medicine, researchers had been conducting "practice runs" on metabolic disorders: simulating how quickly they could create a custom therapy based on a new gene mutation. When KJ was born in August 2024, the team knew this was no longer a drill.Dr. Rebecca Ahrens-Nicklas, a pediatrician at CHOP, and Dr. Kiran Musunuru, a cardiologist at Penn and co-founder of a gene-editing company, led a six-month sprint to develop a treatment just for KJ. Within a week of his birth, his genome was sequenced. It revealed two mutations in the gene responsible for producing an essential liver enzyme.One of the mutations had only been recorded once before — in Japan — meaning this therapy might have just one recipient in the world.Despite the risks and unknowns, the team moved ahead, mindful of past tragedies in experimental gene therapy. Bioethicist Lynn Wein Bush praised the team’s careful approach, saying it didn’t feel rushed, but appropriate for the severity of the disease.A Nationwide EffortScientists across the U.S. rallied to help. The NIH funded a toxicology trial, private companies contributed time and resources, and manufacturing partners created parts of the treatment — one of which was named “kayjayguran” after KJ himself. The FDA fast-tracked regulatory processes to make the therapy available.By February 2025, the experimental drug — made of a CRISPR-based “base editor” encased in a fat bubble — was ready. At nearly seven months old, KJ received his first dose. He slept through it.Signs Of ProgressFollowing the treatment, doctors gradually increased protein in KJ’s diet — something previously impossible — and began reducing ammonia-clearing medication. KJ’s health improved: he’s now eating normally, rolling over, sitting up, and reaching developmental milestones his parents feared he might miss.He’s not cured yet. He still needs monitoring and some medication. But the early signs are encouraging, and the medical community is watching closely.